Malcolm K. Scott
Johnson & Johnson Pharmaceutical Research and Development
37 Papers
402 Citations
Malcolm K. Scott is an academic researcher from Johnson & Johnson Pharmaceutical Research and Development. The author has contributed to research in topics: Benzimidazole & Receptor. The author has an hindex of 13, co-authored 37 publications. Previous affiliations of Malcolm K. Scott include Johnson & Johnson.
Chat about Author
Papers
Patent
Anti-inflammatory compounds
Malcolm K. Scott,Pauline J. Sanfilippo,Louis J. Fitzpatrick,Cardova Richard F,Kevin Pan,Meschino Joseph +5 more
- 29 Dec 1998
TL;DR: In this paper, an invention relates to anti-inflammatory compounds, methods of making such compounds, and methods of using such compounds having the following structure, which is related to anti inflammatory compounds.
67
2,3-Diaryl-5-anilino[1,2,4]thiadiazoles as melanocortin MC4 receptor agonists and their effects on feeding behavior in rats.
Kevin Pan,Malcolm K. Scott,Daniel H. S. Lee,Louis J. Fitzpatrick,Jeffery J Crooke,Ralph A. Rivero,Daniel I. Rosenthal,Anil H. Vaidya,Zhao Boyu,Allen B. Reitz +9 more
TL;DR: 2,3-diaryl-5-anilino[1,2,4]thiadiazoles 3 as potent and selective MC4 receptor agonists are discovered and SAR development on the three attached aryl rings improved the binding affinity from 174 nM to 4.4 nM IC(50).
56
Patent
Method for treating neurodegenerative disorders
Reitz Allen B,David A. Demeter,Daniel H. S. Lee,Hoau-Yan Wang,Robert H. Chen,Tina Morgan Ross,Malcolm K. Scott,Carlos R. Plata-Salamán +7 more
- 27 May 1999
TL;DR: In this paper, a method of treating a neurodegenerative disorder in a subject in need thereof which comprises administering to the subject an amount of a compound effective to inhibit the interaction of amyloid-beta with alpha-7 nicotinic acetylcholine receptors.
54
A New Arylpiperazine Antipsychotic with High D2/D3/5-HT1A/.alpha.1A-Adrenergic Affinity and a Low Potential for Extrapyramidal Effects
Allen B. Reitz,Debra J. Bennett,Paul S. Blum,Ellen E. Codd,Cynthia A. Maryanoff,Marta E. Ortegon,Michael J. Renzi,Malcolm K. Scott,Richard P. Shank,Jeffry L. Vaught +9 more
48
Orally Active Benzamide Antipsychotic Agents with Affinity for Dopamine D2, Serotonin 5-HT1A, and Adrenergic α1 Receptors
Allen B. Reitz,Ellen W. Baxter,Ellen E. Codd,Coralie B. Davis,Alfonzo D. Jordan,Bruce E. Maryanoff,Cynthia A. Maryanoff,Mcdonnell Mark E,Powell Eugene,Michael J. Renzi,Mary R. Schott,Malcolm K. Scott,Richard P. Shank,Jeffry L. Vaught +13 more
TL;DR: The design, synthesis, and evaluation of a series of related (aminomethyl)benzamides in assays predictive of antipsychotic activity in humans, which had notable affinity for dopamine D2, serotonin 5-HT1A, and alpha1-adrenergic receptors are described.
44